Advances in MDS/AML and inositide signalling

Alessia De Stefano; Maria Vittoria Marvi; Antonietta Fazio; James A McCubrey; Pann-Ghill Suh; Stefano Ratti; Giulia Ramazzotti; Lucia Manzoli; Lucio Cocco; Matilde Y Follo

doi:10.1016/j.jbior.2023.100955

Advances in MDS/AML and inositide signalling

Adv Biol Regul. 2023 Jan:87:100955. doi: 10.1016/j.jbior.2023.100955. Epub 2023 Jan 21.

Affiliations

¹ Department of Biomedical Sciences (DIBINEM), University of Bologna, Via Irnerio, 48, 40126, Bologna, Italy.
² Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
³ Korea Brain Research Institute, Daegu, Republic of Korea; School of Life Sciences, UNIST, Ulsan, Republic of Korea.
⁴ Department of Biomedical Sciences (DIBINEM), University of Bologna, Via Irnerio, 48, 40126, Bologna, Italy. Electronic address: [email protected].

PMID: 36706610
DOI: 10.1016/j.jbior.2023.100955

Abstract

Aberrant signaling pathways regulating proliferation and differentiation of hematopoietic stem cells (HSCs) can contribute to disease pathogenesis and neoplastic growth. Phosphoinositides (PIs) are inositol phospholipids that are implicated in the regulation of critical signaling pathways: aberrant regulation of Phospholipase C (PLC) beta1, PLCgamma1 and the PI3K/Akt/mTOR pathway play essential roles in the pathogenesis of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML).

Keywords: Acute myeloid leukemia; Inositides; Myelodysplastic syndromes; PI3K/Akt/mTOR; Signalling.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Myeloid, Acute* / metabolism
Myelodysplastic Syndromes* / metabolism
Phosphatidylinositol 3-Kinases / metabolism
Phosphatidylinositols / metabolism
Signal Transduction / physiology

Substances

Phosphatidylinositol 3-Kinases
Phosphatidylinositols